GHK-Cu and the skin-ageing question: copper peptides under the microscope

Walk the skincare aisle of any premium retailer and you will not get five steps without seeing the word peptide on a box. Most of those peptides are marketing dressed up. GHK-Cu is the one with actual peer-reviewed papers behind its name. People also inject it now.

That second sentence is where this gets interesting, because the two contexts — cosmetic topical and subcutaneous injectable — answer different questions, neither of them as cleanly as the labels imply.

Here is the position once you read past the marketing. The foundational biology of GHK-Cu is real. Forty years of mechanism work is real. Almost all of it traces back to one researcher. The single randomised controlled human trial of GHK-Cu skincare found no objective benefit. The 2025 academic review of topical GHK is still asking whether the peptide even reaches its target through skin. That is the spread you are buying into.

What GHK-Cu is

GHK-Cu is what happens when copper finds glycyl-histidyl-lysine in your bloodstream and binds to it. The tripeptide on its own is GHK. Add a Cu²⁺ ion and you have the molecule with the reputation.

Loren Pickart pulled the underlying tripeptide out of human plasma in the 1970s and worked out, in a 1979 paper in the Journal of Chromatography, that copper and iron co-isolate with it — which is why early attempts to purify GHL kept losing the bioactive material. Remove the transition metals with a chelating resin and recovery went up eight-fold. The paper is short, methodical, and entirely about getting clean peptide. The story of GHK-Cu as a tissue-repair agent is what Pickart built on top of that observation for the next forty years.

The molecule itself sits in plasma, saliva, and urine, and its concentration drops as people age. That last fact — peptide-X declines with age — is the engine of a great deal of longevity marketing, for many compounds, often without the punchline that declines with age and causes ageing are different sentences.

What the mechanism work actually says

The mechanism story for GHK-Cu is unusually detailed for a peptide this small.

Pickart, Vasquez-Soltero and Margolina’s 2015 review in BioMed Research International and the follow-up Pickart and Margolina 2018 paper in the International Journal of Molecular Sciences together lay out a long list of actions. GHK-Cu stimulates the synthesis of collagen, elastin, and the glycosaminoglycans that give skin its bounce. It modulates the metalloproteinases that break those structures down. It supports dermal fibroblasts. It promotes new blood vessel growth, new nerve outgrowth, attracts immune cells to wound sites, and — read across the body of work — accelerates healing in skin, hair follicles, gastrointestinal tract, bone, and stomach lining in rodents, dogs, and pigs.

That is a credible mechanism story. If you give a cell biologist that list and ask whether you would expect topical or systemic GHK-Cu to do something to ageing skin, they would say yes, with a probably. The problem is the next layer.

Almost all of the foundational papers come from Pickart. The 2015 and 2018 reviews above are co-authored from Skin Biology Research & Development — which is Pickart’s own company. The 1979 paper is his too. A great deal of the underlying experimental work was done by him, in his lab, often with the same co-authors over decades.

That does not make it wrong. Some compounds are niche enough that one team does most of the digging. But a forty-year body of work checked mostly by the people most invested in it has not had the outside scrutiny you would normally want before forming a strong belief about what the molecule does. The case rests heavily on one researcher’s career.

The one randomised human trial is the part nobody quotes

This is where the GHK-Cu marketing starts to fail an honest reading.

Miller and colleagues, working at facial-aesthetic practices and writing in the 2006 Archives of Facial Plastic Surgery, ran a randomised controlled trial of GHK-Cu skincare versus placebo. The result was null on the trial’s objective endpoints. Thirteen patients underwent CO₂ laser facial resurfacing — a controlled injury to facial skin, in a setting where you would expect a regenerative peptide to do its most obvious work. Half the patients then used a GHK-Cu skincare regimen during recovery; the other half used the same regimen without the peptide. Resolution of erythema was tracked by computer analysis and by blinded human evaluators. Wrinkles and overall skin quality were assessed at twelve weeks.

The result is the part skincare marketing has spent twenty years not advertising. The blinded evaluators and the computer analysis found no significant difference between groups for any of the objective endpoints. Erythema resolved the same. Wrinkles improved the same. Overall skin quality improved the same. The only outcome that came out positive was a validated patient questionnaire, on which the GHK-Cu users rated their own skin quality higher than the placebo arm did, by a statistically significant margin.

Read that carefully. The objective endpoints — what the laser-resurfaced skin actually looked like under measurement — found GHK-Cu indistinguishable from placebo. The subjective endpoint — what the patients thought of their own faces — found GHK-Cu better than placebo. That is the entire published randomised human evidence base for GHK-Cu skincare. Both findings are honest. They do not tell you the same story.

The trial is also small. Thirteen patients is small even by dermatology standards. A larger trial might find an objective signal the small one missed. But a larger trial has not been run, and the published evidence is the published evidence.

The 2025 academic review is asking the same question

Twenty years after the Miller trial, the academic literature on topical GHK-Cu has not closed the loop.

Mortazavi and colleagues’ 2025 review in Bioimpacts does the thing nobody else has done in print this decade: walks through what is actually known about whether topical GHK gets through skin to do anything. The summary is candid. GHK and its derivatives (GHK-Cu, Pal-GHK) are widely used in commercially available anti-wrinkle products. The published information on their skin permeability, effectiveness, and physicochemical behaviour is — the review’s word — insufficient. We do not have good data on how much topical GHK actually crosses the stratum corneum at the concentrations used in skincare. We do not have good data on what dose reaches the dermal fibroblasts and collagen-producing layers where the mechanism work says it should act. The 2025 paper writes the question out plainly: GHK might be effective; we cannot tell from what has been published.

That is the modern academic position. Not it does not work. Not it works. We cannot tell from what has been published — a position that should be unsettling for a peptide on most premium anti-ageing shelves.

The cosmetic-versus-injection question splits this in two

There is a second, deeper version of the same problem.

The published research on GHK-Cu is split between in-vitro work (cells in dishes), animal models (where the peptide is often applied to wounds or given systemically), and a small set of human studies that — almost all of them — are topical cosmetic-context applications. The one randomised human trial above was a skincare regimen. Most of the rest of the human literature is on copper-peptide-containing creams or post-procedure lotions.

What is now being sold as a peptide injection — subcutaneous GHK-Cu, the way someone uses BPC-157 — is a different application. Subcutaneous injection bypasses the skin-permeability question entirely. It also bypasses the place every published human safety read has been done. The implication is uncomfortable. The published human evidence for GHK-Cu in any form is on topical cosmetic use. The published human evidence for GHK-Cu as an injection is essentially zero.

Two different products with the same molecule and the same marketing. One has thin human data; the other has none.

Where regulators sit — cosmetic vs injectable

GHK-Cu is not on the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee docket. The full list of nominated peptides in the April 2026 Federal Register notice does not include it. That has a clean reading and a complicated one.

The clean reading: GHK-Cu’s regulatory life has been mostly cosmetic. It has sat in skincare under the cosmetic-ingredient framework — labelled, sold, applied topically with relatively few constraints, treated like every other peptide in the ageing-skin aisle. The PCAC docket lane is for substances people want a US licensed compounding pharmacy to make for prescriptions, which is not the cosmetic use case.

The complicated reading: the people injecting GHK-Cu off research-chemical sites are doing exactly the thing PCAC exists to assess — using a compounded peptide on themselves outside the framework — and the agency has scheduled exactly that conversation. GHK-Cu isn’t on the July 23–24 2026 wave, but it is on the second PCAC meeting scheduled before the end of February 2027, alongside Melanotan II, LL-37, Dihexa acetate, and PEG-MGF. And the route detail matters more than the meeting date: the FDA split GHK-Cu by administration, and the two halves moved in opposite directions on the 503A bulk substances lists. Injectable GHK-Cu — the form sold to people drawing it into a syringe — came off Category 2, the FDA’s do not compound list of substances with significant safety concerns. Non-injectable GHK-Cu went the other way: it was pulled out of Category 1, the under evaluation list that had temporarily allowed compounding under enforcement discretion, so topical GHK-Cu lost a safe harbor it used to have. Both forms are slated for the February 2027 consultation. The injectable form is the reason Category 2 had to move, and the reason the compound is on the second-wave docket at all. So the cosmetic regulatory framework will not stay the only place GHK-Cu lives. Until that February meeting, the injection version still sits in a grey zone of established compounding practice. After it, it lives wherever the FDA decides to put it on the Section 503A list.

For WADA, the picture is straightforward. GHK-Cu is not on the prohibited list. Always check the current code on the day of testing.

What would actually settle this

If you want to make a confident decision about GHK-Cu specifically, the evidence that does not yet exist looks like this.

A second randomised controlled trial of topical GHK-Cu in ageing skin — not laser-resurfaced post-procedure skin, but baseline ageing skin — with objective dermatological endpoints, run by a group independent of Pickart and Margolina. Twenty years on, that trial has not been done.

A pharmacokinetic study of subcutaneous GHK-Cu in humans, characterising absorption, distribution, and tissue concentrations. None exists.

A trial of injectable GHK-Cu in any indication, with safety and efficacy endpoints. None exists in the published record.

A skin permeability study answering Mortazavi’s 2025 question directly: at the concentrations used in commercial anti-wrinkle products, does topically applied GHK-Cu reach the dermal layers where the in-vitro mechanism work says it should act. None published with a clean answer.

None of these are difficult studies to run. They are just not the studies that have been funded or published.

The GHK-Cu skincare verdict

The biology of GHK-Cu as a wound-healing and tissue-repair molecule is real, well-described, and unusually deep for a peptide this small. The case for something biological is happening is defensible.

The case for this particular skincare product changes how your face ages rests on the mechanism work plus one negative randomised trial plus a 2025 review that explicitly cannot tell whether the molecule reaches its target through skin. That is a thinner case than the marketing suggests.

The case for injectable GHK-Cu does something for skin ageing or longevity rests on essentially no published human evidence at all. The cosmetic literature does not transfer cleanly to the injection use case, and the injection use case has not been studied in the published record.

GHK-Cu is the most-researched peptide in the cosmetic anti-ageing aisle. Part of that distinction is that the rest of the aisle has nothing. The published evidence supports a modest belief that the molecule is doing something. It does not support the marketing.

That is what we are building. Wolverine Health is a physician-supervised peptide service — real prescriptions, US-licensed compounding pharmacies, every batch third-party tested. It isn’t live yet, because the regulation isn’t either, and we’re not going to sell you ahead of the science. If you want to know the moment the February 2027 PCAC decision on injectable GHK-Cu actually lands — and a legitimate prescribing path opens, separate from the cosmetic aisle — join the waitlist.